Clinical trial
A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT00487539 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- August 31, 2007
- Completion date
- October 31, 2010
- Enrollment
- 1,065 (actual)
- Sites
- 200
Conditions
As the registry lists them; a condition with its own page is linked.